Skip to main content

letter

. 1999 Apr;89(4):602–603. doi: 10.2105/ajph.89.4.602

Directly observed therapy and tuberculosis treatment completion. Bloch re: Bayer et al.

PMCID: PMC1508871 PMID: 10191815

602

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bayer R., Stayton C., Desvarieux M., Healton C., Landesman S., Tsai W. Y. Directly observed therapy and treatment completion for tuberculosis in the United States: is universal supervised therapy necessary? Am J Public Health. 1998 Jul;88(7):1052–1058. doi: 10.2105/ajph.88.7.1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
Bloch A. B., Simone P. M., McCray E., Castro K. G. Preventing multidrug-resistant tuberculosis. JAMA. 1996 Feb 14;275(6):487–489. [PubMed] [Google Scholar]
Chaulk C. P., Moore-Rice K., Rizzo R., Chaisson R. E. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995 Sep 27;274(12):945–951. [PubMed] [Google Scholar]
Weis S. E., Slocum P. C., Blais F. X., King B., Nunn M., Matney G. B., Gomez E., Foresman B. H. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med. 1994 Apr 28;330(17):1179–1184. doi: 10.1056/NEJM199404283301702. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES